The market size of Hemophilia A was found to be USD 6,266 Million in 2017.
The total diagnosed and treated prevalent population of Hemophilia A was found to be 38,212 in 2017 (in the
7MM).
The popularity of Gene Therapy, Development of Novel Treatments with an extended half-life, and Increased Focus on Prophylactic Treatment are some of the leading factors expected to drive the Hemophilia A market in the coming years.
The key players in the Hemophilia A market include Biomarin Pharmaceutical, Novo Nordisk, Sanofi, Pfizer, Catalyst Biosciences, OPKO Biologics, Spark Therapeutics, Sangamo therapeutics and others.
For more details visit: https://www.delveinsight.com/report-store/hemophilia-a2030-market